Citations Report

Citation Index - Clinical Investigation [922 Articles]

The articles published in Clinical Investigation have been cited 922 times by eminent researchers all around the world. Following is the list of articles that have cited the articles published in Clinical Investigation.

  • Oliver DP, Demiris G, Washington K, Kruse RL, Petroski G. Hospice Family Caregiver Involvement in Care Plan Meetings A Mixed-Methods Randomized Controlled Trial. American Journal of Hospice and Palliative Medicine. 2016 Jul 27:1049909116661816.

    View at Publisher | View at Google Scholar
  • Brightling C, Wang M, Braddock M, Nordenmark L, Gottlow M, Colice G. MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma. Clinical Investigation. 2015 Aug;5(8):713-22.

    View at Publisher | View at Google Scholar
  • Jeanblanc NM, Hemken PM, Datwyler MJ, Brophy SE, Manetz TS, Lee R, Liang M, Chowdhury PS, Varkey R, Grant EP, Streicher K. Development of a new ARCHITECT automated periostin immunoassay. Clinica Chimica Acta. 2017 Jan 31;464:228-35.

    View at Publisher | View at Google Scholar
  • de Roos EW, Braunstahl GJ, Lahousse L, Brusselle GG. Targeted Therapy for Older Patients with Uncontrolled Severe Asthma: Current and Future Prospects. Drugs & aging. 2016 Sep 1;33(9):619-28.

    View at Publisher | View at Google Scholar
  • Nixon J, Newbold P, Mustelin T, Anderson GP, Kolbeck R. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacology & Therapeutics. 2017 Jan 31;169:57-77.

    View at Publisher | View at Google Scholar
  • Reichert JM. Antibodies to watch in 2017. InMAbs 2016 Dec 7 (No. just-accepted, pp. 00-00). Taylor & Francis.

    View at Publisher | View at Google Scholar
  • Busse WW, Wang M, Gibson J, Gottlow M, Braddock M, Colice G. TROPOS: designing a clinical trial to evaluate the oral corticosteroid-sparing effect of a biologic in severe asthma. Clin Invest. 2015 Aug;5(8):723-30.

    View at Publisher | View at Google Scholar
  • Brightling C, Wang M, Braddock M, Nordenmark L, Gottlow M, Colice G. MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma. Clinical Investigation. 2015 Aug;5(8):713-22.

    View at Publisher | View at Google Scholar
  • Jeanblanc NM, Hemken PM, Datwyler MJ, Brophy SE, Manetz TS, Lee R, Liang M, Chowdhury PS, Varkey R, Grant EP, Streicher K. Development of a new ARCHITECT automated periostin immunoassay. Clinica Chimica Acta. 2017 Jan 31;464:228-35.

    View at Publisher | View at Google Scholar
  • Rodríguez-Pintó I, Espinosa G, Cervera R. The problems and pitfalls in systemic lupus erythematosus drug discovery.

    View at Publisher | View at Google Scholar
  • Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30;2010(363):2587-99.

    View at Publisher | View at Google Scholar
  • Kenward MG (2015) Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation. Clinical Investigation 5: 311-320.

    View at Publisher | View at Google Scholar
  • Hemmings R, Wright D (2012) Missing data in clinical trials: a data interpretation problem with statistical solutions?. Clinical Investigation 2: 11-17.

    View at Publisher | View at Google Scholar
  • Kenward MG (2015) Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation. Clinical Investigation 5: 311-320.

    View at Publisher | View at Google Scholar
  • Hemmings R, Wright D (2012) Missing data in clinical trials: a data interpretation problem with statistical solutions?. Clinical Investigation 2: 11-17.

    View at Publisher | View at Google Scholar
  • Kenward MG (2015) Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation. Clinical Investigation 5: 311-320.

    View at Publisher | View at Google Scholar
  • Hemmings R, Wright D (2012) Missing data in clinical trials: a data interpretation problem with statistical solutions?. Clinical Investigation 2: 11-17.

    View at Publisher | View at Google Scholar
  • Pujade-Lauraine E, Joly F, Hardy-Bessard AC, Ray-Coquard I, Lecuru F, et al. (2017) Clinical Research in France, Europe, and in the World Dedicated to Ovarian Cancers. InOvarian Cancers: 3-12.

    View at Publisher | View at Google Scholar
  • Malemud CJ (2013) Suppression of pro-inflammatory cytokines via targeting of STAT-responsive genes. INTECH Open Access Publisher.

    View at Publisher | View at Google Scholar
  • Malemud CJ, Blumenthal DE (2014) Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives. World journal of orthopedics 5: 496.

    View at Publisher | View at Google Scholar
  • Malemud CJ (2015) Chondrocyte Apoptosis in Rheumatoid Arthritis: Is Preventive Therapy Possible?. Immunotherapy (Los Angeles, Calif.1.

    View at Publisher | View at Google Scholar
  • Malemud CJ (2014) The Clinical Efficacy of a JAK3-Selective Small Molecule Inhibitor, Tofacitinib. Rheumatoid Arthritis. Austin J Clin Immunol 1: 1021.

    View at Publisher | View at Google Scholar
  • Malemud CJ, Blumenthal DE. Name of journal: World Journal of Orthopedics ESPS Manuscript NO: 8914 Columns: TOPIC HIGHLIGHT.

    View at Publisher | View at Google Scholar
  • Ding HX, Leverett CA, Kyne RE, Liu KK, Sakya SM, et al. (2014) Synthetic approaches to the 2012 new drugs. Bioorganic & medicinal chemistry 22: 2005-2032.

    View at Publisher | View at Google Scholar
  • 韩崇, 朱雄, 徐云根. 蒽环类抗肿瘤化合物的研究进展. 中国新药杂志. 2013;22(3):307-12.

    View at Publisher | View at Google Scholar
  • Paul Krapcho A (2015) Pixuvri®(Pixantrone Dimaleate, BBR 2778): From Lab to Market. Current Organic Chemistry19: 886-897.

    View at Publisher | View at Google Scholar
  • Amorim S, Fleury I, Mounier N, Harel S, Brice P, et al. (2016) Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment. Leukemia & lymphoma 57: 2425-2428.

    View at Publisher | View at Google Scholar
  • Keating GM (2016) Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma. Drugs 76: 1579-1586.

    View at Publisher | View at Google Scholar
  • 朱炎, 朱雄, 周金培. 氮杂蒽酮类抗肿瘤化合物的研究新进展. 药学进展. 2013;37(7):305-12.

    View at Publisher | View at Google Scholar
  • Estrich S. Real rape. Harvard University Press; 1987.

    View at Publisher | View at Google Scholar
  • Glannon W. Bioethics and the brain. Oxford University Press, USA; 2007.

    View at Publisher | View at Google Scholar
  • Burgess-Jackson K. Rape: A philosophical investigation. Brookfield, VT: Dartmouth; 1996 Jan.

    View at Publisher | View at Google Scholar
  • Glannon W. Brain, body, and mind: Neuroethics with a human face. Oxford University Press; 2013 May 2.

    View at Publisher | View at Google Scholar
  • Wallace H, Roberson C. Principles of criminal law. Pearson; 2008.

    View at Publisher | View at Google Scholar
  • Varholy CM. Representing Prostitution in Tudor and Stuart England (Doctoral dissertation, University of Wisconsin, Madison).

    View at Publisher | View at Google Scholar
  • Ajao OG, Ajao OO, Ugwu BT, Yawe KD, Ezeome ER (2014) Factors determining the results of the examination of the West African College of Surgeons in general surgery. Journal of the West African College of Surgeons 4: 1.

    View at Publisher | View at Google Scholar
  • Ostler T, Kopels S (2010) Schizophrenia and filicide. Current Women's Health Reviews 6: 58-62.

    View at Publisher | View at Google Scholar
  • AgheniÅ£ei M (2013) The Environment through Criminal Law in European Union. Revue Européenne du Droit Social 19: 189-194.

    View at Publisher | View at Google Scholar
  • Ingram A (2015) The Good, the Bad, and the Klutzy: Criminal Negligence and Moral Concern. Criminal Justice Ethics 34: 87-115.

    View at Publisher | View at Google Scholar
  • Flaminzeanu I (2013) Environment Criminal Law in Today European Union. AGORA Int'l J. Jurid. Sci: 56.

    View at Publisher | View at Google Scholar
  • Flămînzeanu I (2012) Environment Criminal Law In Today European Union. Contemporary Legal Institutions 4: 109-113.

    View at Publisher | View at Google Scholar
  • Murphy JG (1992) War, Self-Defense, and Defense of Others. InRetribution Reconsidered: 189-200.

    View at Publisher | View at Google Scholar
  • Tomita M (2013) SPECTO 2013.

    View at Publisher | View at Google Scholar
  • AgheniÅ£ei M (2010) Dinamica dreptului românesc în continuitatea prevederilor legii penale. Revista Pro Lege3: 73-93.

    View at Publisher | View at Google Scholar
  • Su C, Hu R, Gu Y, Han R, Yan X, et al. (2016) Liao Q, Huang D. The Nuclear Molecular Imaging of Protein Brain Receptors in Chronic Pain. Current Protein and Peptide Science 17: 559-569.

    View at Publisher | View at Google Scholar
  • Lindblad M, Hougaard A, Amin FM, Ashina M. Can migraine aura be provoked experimentally? A systematic review of potential methods for the provocation of migraine aura. Cephalalgia. 2016 Mar 4:0333102416636097.

    View at Publisher | View at Google Scholar
  • Hu Y, Hu F (2012) Asymptotic properties of covariate-adaptive randomization. The Annals of Statistics 40: 1794-1815.

    View at Publisher | View at Google Scholar
  • Hu F, Hu Y, Ma Z, Rosenberger WF (2014) Adaptive randomization for balancing over covariates. Wiley Interdisciplinary Reviews: Computational Statistics 6: 288-303.

    View at Publisher | View at Google Scholar
  • Ma W, Hu F, Zhang L (2015) Testing hypotheses of covariate-adaptive randomized clinical trials. Journal of the American Statistical Association 110: 669-680.

    View at Publisher | View at Google Scholar
  • Hu J, Zhu H, Hu F (2015) A unified family of covariate-adjusted response-adaptive designs based on efficiency and ethics. Journal of the American Statistical Association 110: 357-367.

    View at Publisher | View at Google Scholar
  • Cheung SH, Zhang LX, Hu F, Chan WS (2014) Covariate-adjusted response-adaptive designs for generalized linear models. Journal of Statistical Planning and Inference 149: 152-161.

    View at Publisher | View at Google Scholar
  • Gaile DP, Miecznikowski JC (2013) From small studies to precision medicine: prioritizing candidate biomarkers. Genome medicine 5: 104.

    View at Publisher | View at Google Scholar
  • Hyun SW, Huang T, Zhu H (2015) Efficient and Ethical Adaptive Clinical Trial Designs to Detect Treatment–Covariate Interaction. InModern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects: 309-326.

    View at Publisher | View at Google Scholar
  • Sverdlov O (2015) An Overview of Adaptive Randomization Designs in Clinical Trials. InModern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects: 3-44.

    View at Publisher | View at Google Scholar
  • Sigaux F (2015) “Digital patient” in hematology and cancerology. Hématologie 21: 60-69.

    View at Publisher | View at Google Scholar
  • Liu SV, Miller VA, Lobbezoo MW, Giaccone G (2014) Genomics-based early-phase clinical trials in oncology: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. European Journal of Cancer 50: 2747-2751.

    View at Publisher | View at Google Scholar
  • Ballantyne A, Rogers W. Pregnancy, vulnerability, and the risk of exploitation in clinical research. InClinical research involving pregnant women 2016 (pp. 139-159). Springer International Publishing.

    View at Publisher | View at Google Scholar
  • Baylis F, MacQuarrie R (2016) Why physicians and women should want pregnant women included in clinical trials. InClinical research involving pregnant women: 17-31.

    View at Publisher | View at Google Scholar
  • Ells C, Lyster C (2016) Research ethics review of drug trials targeting medical conditions of pregnant women. InClinical research involving pregnant women: 95-118.

    View at Publisher | View at Google Scholar
  • Kaposy C (2016) Presumptive inclusion and legitimate exclusion criteria. InClinical research involving pregnant women: 51-62. Springer International Publishing.

    View at Publisher | View at Google Scholar
  • Schmidt AF, Groenwold RH, Van Delden JJ, Van Der Does Y, Klungel OH, et al. (2014) Justification of exclusion criteria was underreported in a review of cardiovascular trials. Journal of clinical epidemiology 67: 635-644.

    View at Publisher | View at Google Scholar
  • Clemow DB, Dewulf L, Michaels DL, Nolan MR, Cantrell SA (2014) A proposed framework to address needs of clinical data for informed medication use in pregnancy. Therapeutic Innovation & Regulatory Science 48: 145-154.

    View at Publisher | View at Google Scholar
  • Matsui D (2015) Ethics of studies of drugs in pregnancy. Pediatric Drugs 17: 31-35.

    View at Publisher | View at Google Scholar
  • Clemow DB, Dewulf L, Koren G, Mikita JS, Nolan MR, et al. (2014) Clinical data for informed medication use in pregnancy: strengths, limitations, gaps, and a need to continue moving forward. Therapeutic Innovation & Regulatory Science 48: 134-144.

    View at Publisher | View at Google Scholar
  • Baylis F, Ballantyne A (2016) Missed trials, future opportunities. InClinical research involving pregnant women: 1-13.

    View at Publisher | View at Google Scholar
  • Clemow DB, Nolan MR, Michaels DL, Kogelnik AM, Cantrell SA, et al. (2015) Dewulf L. Medicines in pregnancy forum: Proceedings on ethical and legal considerations. Therapeutic Innovation & Regulatory Science 49: 326-332.

    View at Publisher | View at Google Scholar
  • Briggs GG, Polifka JE, Wisner KL, Gervais E, Miller RK, et al. (2015) Should pregnant women be included in phase IV clinical drug trials?. American journal of obstetrics and gynecology 213: 810-815.

    View at Publisher | View at Google Scholar
  • Ravinetto R, Schwartz L (2016) Research Ethics Governance in Times of Ebola. PUBLIC HEALTH 1: 13.

    View at Publisher | View at Google Scholar
  • Schopper D, Ravinetto R, Schwartz L, Kamaara E, Sheel S, et al. (2016) Research Ethics Governance in Times of Ebola. Public Health Ethics 1: 039.

    View at Publisher | View at Google Scholar
  • Rosenfeld JV, Maas AI, Bragge P, Morganti-Kossmann MC, Manley GT, et al. (2012) Early management of severe traumatic brain injury. The Lancet 380: 1088-1098.

    View at Publisher | View at Google Scholar
  • Lingsma H, Andriessen TM, Haitsema I, Horn J, van der Naalt J, et al. (2013) Prognosis in moderate and severe traumatic brain injury: external validation of the IMPACT models and the role of extracranial injuries. Journal of trauma and acute care surgery 74: 639-646.

    View at Publisher | View at Google Scholar
  • Stein DG (2015) Embracing failure: what the phase III progesterone studies can teach about TBI clinical trials. Brain injury 29: 1259-1272.

    View at Publisher | View at Google Scholar
  • Hutchison JS, Guerguerian AM (2013) Cooling of children with severe traumatic brain injury. The Lancet Neurology 12: 527-529.

    View at Publisher | View at Google Scholar
  • Paul F (2013) Hope for a rare disease: eculizumab in neuromyelitis optica. The Lancet Neurology 12: 529-531.

    View at Publisher | View at Google Scholar
  • Xiong Y, Zhang Y, Mahmood A, Chopp M (2015) Investigational agents for treatment of traumatic brain injury. Expert opinion on investigational drugs 24: 743-760.

    View at Publisher | View at Google Scholar
  • Bragge P, Synnot A, Maas AI, Menon DK, Cooper DJ, et al. (2016) A state-of-the-science overview of randomized controlled trials evaluating acute management of moderate-to-severe traumatic brain injury. Journal of neurotrauma 33: 1461-1478.

    View at Publisher | View at Google Scholar
  • Stein DG. Lost in translation: understanding the failure of the progesterone/traumatic brain injury Phase III trials.

    View at Publisher | View at Google Scholar
  • Nunn A, Bath PM, Gray LJ (2016) Analysis of the Modified Rankin Scale in Randomised Controlled Trials of Acute Ischaemic Stroke: A Systematic Review. Stroke research and treatment 20.

    View at Publisher | View at Google Scholar
  • Lazaridis C, Maas AI, Souter MJ, Martin RH, Chesnut RM, et al. (2015) Second Neurocritical Care Research Conference Investigators. Alternative Clinical Trial Design in Neurocritical Care. Neurocritical care 22: 378-384.

    View at Publisher | View at Google Scholar
  • Markovic G, Schult ML, Bartfai A (2016) The effect of sampling bias on generalizability in intervention trials after brain injury. Brain injury 6: 1-7.

    View at Publisher | View at Google Scholar
  • Staples JA, Wang J, Mills B, Temkin N, Zaros MC, et al. (2016) Jurkovich GJ, Rivara FP. The Application of the CRASH-CT Prognostic Model for Older Adults With Traumatic Brain Injury: A Population-Based Observational Cohort Study. The Journal of head trauma rehabilitation 31: 8-14.

    View at Publisher | View at Google Scholar
  • van Essen TA, De Ruiter GC, Kho KH, Peul WC (2016)Neurosurgical Treatment Variation of Traumatic Brain Injury: Evaluation of Acute Subdural Hematoma Management in Belgium and The Netherlands. Journal of neurotrauma..

    View at Publisher | View at Google Scholar
  • Gronbeck KR, Rodrigues CM, Mahmoudi J, Bershad EM, Ling G, (2016) Application of Tauroursodeoxycholic Acid for Treatment of Neurological and Non-neurological Diseases: Is There a Potential for Treating Traumatic Brain Injury?. Neurocritical care 25: 153-166.

    View at Publisher | View at Google Scholar
  • Roquilly A, Asehnoune K (2014) Traitement de l’hypertension intracrânienne post-traumatique: quel impact sur le devenir des patients?. InAnnales francaises d'anesthesie et de reanimation 1: 6-7.

    View at Publisher | View at Google Scholar
  • Flume PA, Van Devanter DR (2012) State of progress in treating cystic fibrosis respiratory disease. BMC medicine 10: 88.

    View at Publisher | View at Google Scholar
  • VanDevanter DR, Pasta DJ, Konstan MW (2014) Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012. The Journal of pediatrics 165: 1091-1097.

    View at Publisher | View at Google Scholar
  • VanDevanter DR, Kahle JS, O’Sullivan AK, Sikirica S, Hodgkins PS (2016) Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment. Journal of Cystic Fibrosis 15: 147-157.

    View at Publisher | View at Google Scholar
  • VanDevanter DR, Pasta DJ, Konstan MW (2015) Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis 14: 763-769.

    View at Publisher | View at Google Scholar
  • Dasenbrook EC, Konstan MW, VanDevanter DR (2015) Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. Journal of Cystic Fibrosis 14: 370-375.

    View at Publisher | View at Google Scholar
  • Dasenbrook EC, Konstan MW (2012) Inhaled hypertonic saline in infants and young children with cystic fibrosis 307: 2316-2317.

    View at Publisher | View at Google Scholar
  • Torphy TJ, Allen J, Cantin AM, Konstan MW, Accurso FJ, et al. (2015) Considerations for the conduct of clinical trials with antiinflammatory agents in cystic fibrosis. A Cystic Fibrosis Foundation Workshop Report. Annals of the American Thoracic Society 12: 1398-1406.

    View at Publisher | View at Google Scholar
  • VanDevanter DR, Morris NJ, Konstan MW (2016) IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis 15: 372-379.

    View at Publisher | View at Google Scholar
  • Thornton CS, Brown EL, Alcantara J, Rabin HR, Parkins MD (2015) Prevalence and impact of S treptococcus pneumoniae in adult cystic fibrosis patients: a retrospective chart review and capsular serotyping study. BMC pulmonary medicine 15: 49.

    View at Publisher | View at Google Scholar
  • Szczesniak R, Turkovic L, Andrinopoulou ER, Tiddens HA (2016) Chest imaging in cystic fibrosis studies: What counts, and can be counted?. Journal of Cystic Fibrosis.

    View at Publisher | View at Google Scholar
  • Szczesniak R, Heltshe SL, Stanojevic S, Mayer-Hamblett N. Use of FEV 1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.

    View at Publisher | View at Google Scholar
  • Flume PA, VanDevanter DR. The challenges of maintaining momentum in CF drug development and approval.

    View at Publisher | View at Google Scholar
  • Uria AR (2015) Capturing Natural Product Biosynthetic Pathways from Uncultivated Symbiotic Bacteria of Marine Sponges Through Metagenome Mining: A Mini-Review. Squalen Bulletin of Marine and Fisheries Postharvest and Biotechnology 10: 35-49.

    View at Publisher | View at Google Scholar
  • Halvorsrud L, Kalfoss M (2014) Quality of life data in older adults: self-assessment vs interview. British Journal of Nursing 23.

    View at Publisher | View at Google Scholar
  • Harrington JA, Wheeler GM, Sweeting MJ, Mander AP, Jodrell DI (2013) Adaptive designs for dual-agent phase I dose-escalation studies. Nature Reviews Clinical Oncology 10: 277-288.

    View at Publisher | View at Google Scholar
  • Elsäßer A, Regnstrom J, Vetter T, Koenig F, Hemmings RJ, et al. (2014) Greco M, Papaluca-Amati M, Posch M. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials 15: 383.

    View at Publisher | View at Google Scholar
  • Miller F, Björnsson M, Svensson O, Karlsten R (2014) Experiences with an adaptive design for a dose-finding study in patients with osteoarthritis. Contemporary clinical trials 37: 189-199.

    View at Publisher | View at Google Scholar
  • Cuffe RL, Lawrence D, Stone A, Vandemeulebroecke M (2014) When is a seamless study desirable? Case studies from different pharmaceutical sponsors. Pharmaceutical statistics 13: 229-237.

    View at Publisher | View at Google Scholar
  • Zhang L, Rosenberger WF (2014) Response-Adaptive Randomization for Clinical Trials. InPractical Considerations for Adaptive Trial Design and Implementation: 183-199.

    View at Publisher | View at Google Scholar
  • Rakemann T. A comparative study of the different approaches for approval of new HIV drugs to guidelines of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) including possible implications on future drug development (Doctoral dissertation, Rheinische Friedrich-Wilhelms-Universität Bonn).

    View at Publisher | View at Google Scholar
  • Esparza J (2013) A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 31: 3502-3518.

    View at Publisher | View at Google Scholar
  • Excler JL, Tomaras GD, Russell ND (2013) Novel directions in HIV-1 vaccines revealed from clinical trials. Current opinion in HIV and AIDS 8: 421-431.

    View at Publisher | View at Google Scholar
  • A Day T, G Kublin J (2013) Lessons learned from HIV vaccine clinical efficacy trials. Current HIV research 11: 441-449.

    View at Publisher | View at Google Scholar
  • Lithgow KV, Cameron CE (2017) Vaccine development for syphilis. Expert Review of Vaccines 16: 37-44.

    View at Publisher | View at Google Scholar
  • Gilbert PB. 2. Biographical Information.

    View at Publisher | View at Google Scholar
  • Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, et al. (2014) Long-term mortality in HIV-positive individuals virally suppressed for> 3 years with incomplete CD4 recovery. Clinical infectious diseases 58: 1312-1321.

    View at Publisher | View at Google Scholar
  • Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, et al. (2014) An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. PloS one 9: 86719.

    View at Publisher | View at Google Scholar
  • Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, et al. (2014) Evaluation of rapid progressors in HIV infection as an extreme phenotype. JAIDS Journal of Acquired Immune Deficiency Syndromes 67: 15-21.

    View at Publisher | View at Google Scholar
  • Giganti MJ, Luz PM, Caro-Vega Y, Cesar C, Padgett D, et al. (2015) Koenig S, Echevarria J, McGowan CC, Shepherd BE. A comparison of seven cox regression-based models to account for heterogeneity across multiple HIV treatment cohorts in Latin America and the Caribbean. AIDS research and human retroviruses 31: 496-503.

    View at Publisher | View at Google Scholar
  • Judd A, Duong T, Galli L, Goetghebuer T, Ene L, et al. (2014) Post‐licensing safety of fosamprenavir in HIV‐infected children in Europe. pharmacoepidemiology and drug safety 23: 321-325.

    View at Publisher | View at Google Scholar
  • Jarrin I, Pantazis N, Dalmau J, Phillips AN, Olson A, et al. (2015) Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. AIDS 29: 2323-2333.

    View at Publisher | View at Google Scholar
  • Olson AD, Walker AS, Suthar AB, Sabin C, Bucher HC, et al. (1999) Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death. Journal of acquired immune deficiency syndromes 73: 100.

    View at Publisher | View at Google Scholar
  • Fidler S, Olson AD, Bucher HC, Fox J, Thornhill J, et al. (2017) Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 74: 126-133.

    View at Publisher | View at Google Scholar
  • Donaldson AE, Gordon MS, Melvin GA, Barton DA, Fitzgerald PB (2014) Addressing the needs of adolescents with treatment resistant depressive disorders: a systematic review of rTMS. Brain stimulation 7: 7-12.

    View at Publisher | View at Google Scholar
  • Gordon M, Melvin G (2014) Risk assessment and initial management of suicidal adolescents. Australian family physician 43: 367.

    View at Publisher | View at Google Scholar
  • Krige A, Pattison N, Booth M, Walsh T. Co-enrolment to intensive care studies–a UK perspective.

    View at Publisher | View at Google Scholar
  • Huang DT, Angus DC, Moss M, Thompson BT, Ferguson ND, et al. (2017) Ginde A, Gong MN, Gundel S, Hayden DL, Hite RD, Hou PC. Design and Rationale of the Reevaluation of Systemic Early Neuromuscular Blockade Trial for Acute Respiratory Distress Syndrome. Annals of the American Thoracic Society 14: 124-33.

    View at Publisher | View at Google Scholar
  • Mah R, Thomas JR, Shafer CM. Drug discovery considerations in the development of covalent inhibitors. Bioorganic & medicinal chemistry letters. 2014 Jan 1;24(1):33-9.

    View at Publisher | View at Google Scholar
  • Zhou W, Liu X, Tu Z, Zhang L, Ku X, et al. (2013) Discovery of Pteridin-7 (8 H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) Kinase T790M/L858R mutant. Journal of medicinal chemistry 56: 7821-7837.

    View at Publisher | View at Google Scholar
  • Qin X, Li Z, Yang L, Liu P, Hu L, et al. (2016) Discovery of new [1, 4] dioxino [2, 3-f] quinazoline-based inhibitors of EGFR including the T790M/L858R mutant. Bioorganic & medicinal chemistry 24: 2871-2881.

    View at Publisher | View at Google Scholar
  • Hughes-Morley A, Young B, Waheed W, Small N, Bower P (2015) Factors affecting recruitment into depression trials: systematic review, meta-synthesis and conceptual framework. Journal of affective disorders 172: 274-290.

    View at Publisher | View at Google Scholar
  • Crome P, Cherubini A, Oristrell J (2014) The PREDICT (increasing the participation of the elderly in clinical trials) study: the charter and beyond. Expert review of clinical pharmacology 7: 457-468.

    View at Publisher | View at Google Scholar
  • Barton S, Karner C, Salih F, Baldwin DS, Edwards SJ (2014) Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. Health Technology Assessment 18: 1-60.

    View at Publisher | View at Google Scholar
  • Parsons S, Starling B, Mullan-Jensen C, Tham SG, Warner K, et al. (2015) What the public knows and wants to know about medicines research and development: a survey of the general public in six European countries. BMJ open 5: e006420.

    View at Publisher | View at Google Scholar
  • De Spiegeleer B, Wynendaele E, Bracke N, Veryser L, Taevernier L, et al. (2016) Degroote A, Stalmans S. Regulatory development of geriatric medicines: To GIP or not to GIP?. Ageing research reviews 27: 23-36.

    View at Publisher | View at Google Scholar
  • Bartlam B, Waterfield J, Bishop A, Holden MA, Barlas P, et al. (2016) Ismail KM, Kettle C, Foster NE. The Role of Qualitative Research in Clinical Trial Development The EASE Back Study. Journal of Mixed Methods Research 13:1558689816656740.

    View at Publisher | View at Google Scholar
  • Cherubini A, Crome P (2016) The exclusion of older subjects from clinical trials. Clinical trials in older adults 12: 1-22.

    View at Publisher | View at Google Scholar
  • Crome AC (2015) The exclusion of older subjects from clinical trials: the PREDICT study. Clinical Trials in Older Adults 28: 1.

    View at Publisher | View at Google Scholar
  • Farrand P, Matthews J, Dickens C, Anderson M, Woodford J (2016) Psychological interventions to improve psychological well-being in people with dementia or mild cognitive impairment: systematic review and meta-analysis protocol. BMJ open 6: e009713.

    View at Publisher | View at Google Scholar
  • Lavan A, Gallagher P, O’Mahony D (2016) Future Perspectives in Drug Therapy of Older Adults. InDeveloping Drug Products in an Aging Society: 737-757.

    View at Publisher | View at Google Scholar
  • Crome P, Pleming J (2016) Healthcare Provision in an Aging Society—The European Perspective. InDeveloping Drug Products in an Aging Society: 23-44.

    View at Publisher | View at Google Scholar
  • Rouette J, Blazeby J, King M, Calvert M, Peng Y, et al. (2015)Meyer RM, Ringash J, Walker M, Brundage MD. Integrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists’ perspectives. Quality of Life Research 24: 1317-1325.

    View at Publisher | View at Google Scholar
  • Bantug ET, Coles T, Smith KC, Snyder CF, Rouette J, Brundage (2016) Graphical displays of patient-reported outcomes (PRO) for use in clinical practice: What makes a pro picture worth a thousand words?. Patient education and counseling 99: 483-490.

    View at Publisher | View at Google Scholar
  • Bratton DJ. Design issues and extensions of multi-arm multi-stage clinical trials (Doctoral dissertation, UCL (University College London)).

    View at Publisher | View at Google Scholar
  • Dauti A, Gerstl B, Chong S, Chisholm O, Anazodo A (2017) Improvements in Clinical Trials Information Will Improve the Reproductive Health and Fertility of Cancer Patients. Journal of Adolescent and Young Adult Oncology. 2017 Feb 16.

    View at Publisher | View at Google Scholar
  • Tan CJ, Yang JL, Crowe P, Goldstein D (2013) Targeted therapy in soft tissue sarcoma—a novel direction in therapeutics. Chinese clinical oncology 2.

    View at Publisher | View at Google Scholar
  • Rothschild SI, Gautschi O, Batliner J, Gugger M, Fey MF, et al. (2016) MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. Lung Cancer.

    View at Publisher | View at Google Scholar
  • Amarilyo G, Lourenço EV, Shi FD, La Cava A (2014) IL-17 promotes murine lupus. The Journal of Immunology 193: 540-243.

    View at Publisher | View at Google Scholar
  • Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M, et al. (2016) Pinkerton JV. Compounded bioidentical hormones in endocrinology practice: an endocrine society scientific statement. The Journal of Clinical Endocrinology & Metabolism. 2016 Apr 1;101(4):1318-43.

    View at Publisher | View at Google Scholar
  • Durham NC. Personal Information Name: Prema Menezes.

    View at Publisher | View at Google Scholar
  • Jang IS, Neto EC, Guinney J, Friend SH, Margolin AA (2014) Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. InPacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 2014 (p. 63). NIH Public Access.

    View at Publisher | View at Google Scholar
  • Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers CL (2015) Identification of an oncogenic RAB protein. Science 350: 211-217.

    View at Publisher | View at Google Scholar
  • Jang IS, Dienstmann R, Margolin AA, Guinney J (2015) STEPWISE GROUP SPARSE REGRESSION (SGSR): GENE-SET-BASED PHARMACOGENOMIC PREDICTIVE MODELS WITH STEPWISE SELECTION OF FUNCTIONAL PRIORS. InPacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 20: 32.

    View at Publisher | View at Google Scholar
  • Ennis L, Wykes T (2013) Impact of patient involvement in mental health research: longitudinal study. The British Journal of Psychiatry 203: 381-386.

    View at Publisher | View at Google Scholar
  • Sin J, Henderson C, Spain D, Gamble C, Norman I (2016) What factors influence successful recruitment of siblings of individuals with first episode psychosis to e‐health interventions? A qualitative study. Health Expectations.

    View at Publisher | View at Google Scholar
  • Ziegler D, Fonseca V (2015) From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. Journal of Diabetes and its Complications 29: 146-156.

    View at Publisher | View at Google Scholar
  • O’Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014 Jan 1;74(1):15-30.

    View at Publisher | View at Google Scholar
  • Bröker M, Jacobsson S, Kuusi M, Pace D, Simões MJ, Skoczynska A, Taha MK, Toropainen M, Tzanakaki G. Meningococcal serogroup Y emergence in Europe: update 2011. Human vaccines & immunotherapeutics. 2012 Dec 1;8(12):1907-11.

    View at Publisher | View at Google Scholar
  • Hellenbrand W, Koch J, Harder T, Bogdan C, Heininger U, et al. (2015) Tenenbaum T, Terhardt M, Vogel U, Wichmann O, von Kries R. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 58: 1314-1343.

    View at Publisher | View at Google Scholar
  • Zwiauer KF, Bröker M, Banzhoff A (2014) Der neue Mehrfachkomponentenimpfstoff 4CMenB zum Schutz vor Erkrankungen durch Meningokokken der Serogruppe B. Pädiatrie & Pädologie 49: 3-12.

    View at Publisher | View at Google Scholar
  • Keogh J, Krägeloh CU, Shepherd D, Ryan C, Osborne S, et al. (2013) Quantitative assessment of quality of life in New Zealand prostate cancer survivors: the effect of androgen deprivation therapy. Journal of Cancer Research and Therapy 1: 105-110.

    View at Publisher | View at Google Scholar
  • Li X, Xue H, Kang Q, Sun H, Yang S, et al. (2014) Alterations of the interstitial cells of Cajal and the microstructure of the gastrointestinal tract in KIT distal kinase mutant mice. Cell and tissue research 355: 49-58.

    View at Publisher | View at Google Scholar
  • Scherer DG, Brody JL, Annett RD, Turner C, Dalen J, et al. (2013) Empirically derived knowledge on adolescent assent to pediatric biomedical research. AJOB primary research 4: 15-26.

    View at Publisher | View at Google Scholar
  • Calvert M, Kyte D, Duffy H, Gheorghe A, Mercieca-Bebber R, et al. (2014) Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PloS one 9: e110216.

    View at Publisher | View at Google Scholar
  • Licitra L, Mesía R, Keilholz U (2016) Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck. Oral oncology 52: 18-23.

    View at Publisher | View at Google Scholar
  • Hahn EA, Kallen MA, Jensen RE, Potosky AL, Moinpour CM, et al. (2016) Measuring Social Function in Diverse Cancer Populations: Evaluation of Measurement Equivalence of the Patient Reported Outcomes Measurement Information System®(PROMIS®) Ability to Participate in Social Roles and Activities Short Form. Psychological Test and Assessment Modeling 58: 403.

    View at Publisher | View at Google Scholar
  • Cella D, Teresi JA. Elizabeth A. Hahn1, Michael A. Kallen2, Roxanne E. Jensen3, Arnold L. Potosky3, Carol M. Moinpour4, Mildred Ramirez5.

    View at Publisher | View at Google Scholar
  • Hepgur M, Sadeghi S, Dorff TB, Quinn DI (2013)Tivozanib in the treatment of renal cell carcinoma. Biologics 7: 139-148.

    View at Publisher | View at Google Scholar
  • Hampson LV, Whitehead J, Eleftheriou D, Brogan P (2014) Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Statistics in medicine 33: 4186-4201.

    View at Publisher | View at Google Scholar
  • Billingham L, Malottki K, Steven N (2016) Research methods to change clinical practice for patients with rare cancers. The Lancet Oncology 17: e70-e80.

    View at Publisher | View at Google Scholar
  • Hampson LV, Herold R, Posch M, Saperia J, Whitehead A (2014) Bridging the gap: a review of dose investigations in paediatric investigation plans. British journal of clinical pharmacology 78: 898-907.

    View at Publisher | View at Google Scholar
  • Hincapié CA, Cassidy JD, Rampersaud R, Pierre Côté DC, Jadad AR, Tomlinson GA. Chiropractic Spinal Manipulation Treatment and the Risk For 3 Acute Lumbar Disc Herniation: A Belief Elicitation Study. Chiropractic Care and Risk For Acute Lumbar Disc Herniation: A Mixed Methods Approach. 2015:65.

    View at Publisher | View at Google Scholar
  • i Alapont VM, Khemani RG, Medina A, del Villar Guerra P, Cambra AM. Bayes to the Rescue: Continuous Positive Airway Pressure Has Less Mortality Than High-Flow Oxygen. Pediatric Critical Care Medicine. 2017 Feb 1;18(2):e92-9.

    View at Publisher | View at Google Scholar
  • Brard C, Le Teuff G, Le Deley MC, Hampson LV. Bayesian survival analysis in clinical trials: What methods are used in practice?. Clinical Trials. 2016 Oct 10:1740774516673362.

    View at Publisher | View at Google Scholar
  • Lewiecki EM (2011) Welcome to Clinical Investigation. Clinical Investigation (1):1-2.

    View at Publisher | View at Google Scholar
  • Lu B, Nagappan G, Guan X, Nathan PJ, Wren P (2013) BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature Reviews Neuroscience 14: 401-416.

    View at Publisher | View at Google Scholar
  • Lu B, Nagappan G, Nathan PJ, Blin O (2013) Synaptic function as a preclinical and experimental medicine readout for disease-modifying therapy in Alzheimer's Disease. Drug Discovery Today: Therapeutic Strategies 10: e99-e104.

    View at Publisher | View at Google Scholar
  • (2011) Infectious Diseases Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clinical Infectious Diseases May 1;52(suppl 5):S397-428.

    View at Publisher | View at Google Scholar
  • Young JS, Simmons JW (2014) Chemotherapeutic medications and their emergent complications. Emergency medicine clinics of North America 32: 563-578.

    View at Publisher | View at Google Scholar
  • (2012) Infectious Diseases Society of America. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clinical Infectious Diseases. Aug 13:cis688.

    View at Publisher | View at Google Scholar
  • Spellberg B, Bartlett J, Wunderink R, Gilbert DN (2015) Novel approaches are needed to develop tomorrow’s antibacterial therapies. American journal of respiratory and critical care medicine191(2):135-40.

    View at Publisher | View at Google Scholar
  • Spellberg B (2014) The future of antibiotics. Critical care 18(3):228.

    View at Publisher | View at Google Scholar
  • Favaloro EJ, Plebani M, Lippi G (2013) Regulation in hemostasis and thrombosis: part I—in vitro diagnostics. InSeminars in thrombosis and hemostasis 39: 235-249.

    View at Publisher | View at Google Scholar
  • Shlaes DM, Spellberg B (2012) Overcoming the challenges to developing new antibiotics. Current opinion in pharmacology 12(5):522-6.

    View at Publisher | View at Google Scholar
  • Favaloro EJ. Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions. InSeminars in thrombosis and hemostasis 2014 Jul (Vol. 40, No. 05, pp. 551-570). Thieme Medical Publishers.

    View at Publisher | View at Google Scholar
  • Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, et al. (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease. Circulation : CIR-0000000000000031.

    View at Publisher | View at Google Scholar
  • Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, et al. (2006) ACC/AHA 2006 practice guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of .... Journal of the American College of Cardiology 48: 598-675.

    View at Publisher | View at Google Scholar
  • Guyton RA, Sundt III TM, Albert NM, Hochman FJ, Bozkurt FB, et al. (2014) 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. Circulation129:000-.

    View at Publisher | View at Google Scholar
  • Albert NM, Bozkurt B, Curtis LH, DeMets D, Guyton RA, et al. (2014) AHA/ACC Guideline. Circulation 129: e521-e643.

    View at Publisher | View at Google Scholar
  • Albert NM, Bozkurt FB, Brindis FR, Curtis LH, DeMets FD, et al. (2014) AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary.

    View at Publisher | View at Google Scholar
  • Hennekens CH, Borzak S, Bjorkman DJ. Cardiovascular risks of cyclooxygenase-2 inhibitors and traditional anti-inflammatory drugs: necessary but not sufficient for clinical decision making.

    View at Publisher | View at Google Scholar
  • Fleming TR, Hennekens CH, Pfeffer MA, DeMets DL (2014) Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials. Journal of biopharmaceutical statistics 24(5):968-75.

    View at Publisher | View at Google Scholar
  • Garber AJ, Newcomer JW, Hennekens CH (2013) Lower A1c targets in type 2 diabetes and increased mortality: causal or casual?. The American journal of medicine 126(12):1033-4.

    View at Publisher | View at Google Scholar
  • Wittes J (2016) Independent Data Monitoring Committees in Multiregional Clinical Trials. InMultiregional Clinical Trials for Simultaneous Global New Drug Development (pp. 151-166).

    View at Publisher | View at Google Scholar
  • Mason PH, Degeling C (2016) Beyond biomedicine: Relationships and care in tuberculosis prevention. Journal of bioethical inquiry. 13: 31-34.

    View at Publisher | View at Google Scholar
  • Lewiecki EM (2011) Welcome to Clinical Investigation. Clinical Investigation (1):1-2.

    View at Publisher | View at Google Scholar
  • Qi H, Chen L, Liu B, Wang X, Long L, et al. (2014) Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents. Bioorganic & medicinal chemistry letters 24(4):1108-10.

    View at Publisher | View at Google Scholar
  • Arreola A, Rathmell WK (2013) Biology of Renal Cell Carcinoma (Vascular Endothelial Growth Factor, Mammalian Target of Rapamycin, Immune Aspects). InRenal Cell Carcinoma (pp. 231-247)

    View at Publisher | View at Google Scholar
  • Giuffrè G, Ieni A, Barresi V, Caruso RA, Tuccari G (2012) HER2 status in unusual histological variants of gastric adenocarcinomas. Journal of clinical pathology 65(3):237-41.

    View at Publisher | View at Google Scholar
  • Park SR, Park YS, Ryu MH, Ryoo BY, Woo CG et al. (2016) Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). European Journal of Cancer 53:42-50.

    View at Publisher | View at Google Scholar
  • Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB (2012) Denosumab for the Prevention of Skeletal‐Related Events in Patients with Bone Metastasis from Solid Tumor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32(3):274-84.

    View at Publisher | View at Google Scholar
  • Salesi M, Mottaghi P, Karimifar M, Farajzadegan Z (2012) Intravenous pamidronate for refractory rheumatoid arthritis. Journal of Research in Medical Sciences 17(5).

    View at Publisher | View at Google Scholar
  • 李红星, 柳立军, 景原雪, 刘梦伊, 薛石龙. 促性腺激素释放激素拮抗剂在性激素依赖性疾病中的应用. 中国新药杂志. 2012;21(20):2394-7.

    View at Publisher | View at Google Scholar
  • Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J (2013) Targeting signaling pathways in epithelial ovarian cancer. International journal of molecular sciences 14: 9536-9555.

    View at Publisher | View at Google Scholar
  • Garces ÁH, Dias MS, Paulino E, Ferreira CG, de Melo AC (2015) Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?. Cancer chemotherapy and pharmacology. 75: 221-234.

    View at Publisher | View at Google Scholar
  • Choonara I (2014) Paediatric research environment in the UK. Paediatrics and Child Health 24: 370-373.

    View at Publisher | View at Google Scholar
  • Laufs U (2014) Descamps OS, Catapano AL, Packard CJ. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. European heart journal Jun 10:ehu228.

    View at Publisher | View at Google Scholar
  • Helms PJ, Dicks P (2013) The Scottish Children's Research Network: challenges, opportunities and achievements. Clinical Investigation 3: 433-439.

    View at Publisher | View at Google Scholar
  • Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?. Diabetes. 2012 Sep 1;61(9):2199-204.

    View at Publisher | View at Google Scholar
  • Wright EM. Glucose transport families SLC5 and SLC50. Molecular aspects of medicine. 2013 Jun 30;34(2):183-96.

    View at Publisher | View at Google Scholar
  • Brand T, Macha S, Mattheus M, Pinnetti S, Woerle HJ (2012) Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Advances in therapy. 1:1-1.

    View at Publisher | View at Google Scholar
  • Misra M (2013) SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. Journal of Pharmacy and Pharmacology 65(3):317-27.

    View at Publisher | View at Google Scholar
  • Macha S, Dieterich S, Mattheus M, Seman LJ, Broedl UC et al. (2013) Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. International journal of clinical pharmacology and therapeutics (2):132-40.

    View at Publisher | View at Google Scholar
  • Kanwal A, Banerjee SK (2013) SGLT inhibitors: a novel target for diabetes. Pharmaceutical patent analyst (1):77-91.

    View at Publisher | View at Google Scholar
  • Yamaguchi K, Kato M, Suzuki M, Hagita H, Takada M, Ayabe M, Aso Y, Ishigai M, Ikeda S. In vitro–in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. Journal of Pharmacology and Experimental Therapeutics. 2013 Apr 1;345(1):52-61.

    View at Publisher | View at Google Scholar
  • Zhang Q, Dou J, Lu J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses. Diabetes research and clinical practice. 2014 Sep 30;105(3):313-21.

    View at Publisher | View at Google Scholar
  • 王小彦, 王玉丽, 徐为人. 近几年治疗糖尿病热点靶点的研究进展. 药物评价研究. 2012 Feb.

    View at Publisher | View at Google Scholar
  • Yamaguchi K, Kato M, Ozawa K, Kawai T, Yata T et al. (2012) Pharmacokinetic and pharmacodynamic modeling for the effect of sodium–glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice. Journal of pharmaceutical sciences 101(11):4347-56.

    View at Publisher | View at Google Scholar
  • Deshmukh AB, Patel MC, Mishra B (2013) SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus. Renal failure 35(4):566-72.

    View at Publisher | View at Google Scholar
  • Malla P, Kumar R, Mahapatra MK, Kumar M (2014) Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure. Medicinal research reviews 34(6):1146-67.

    View at Publisher | View at Google Scholar
  • Liu J, Lee T (2011) 7 SGLT2 Inhibitors for Type 2 Diabetes. Annual Reports in Medicinal Chemistry. 46:103

    View at Publisher | View at Google Scholar
  • Cersosimo E, Solis-Herrera C, Triplitt C (2014) Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients. Jornal Brasileiro de Nefrologia 36(1):80-92.

    View at Publisher | View at Google Scholar
  • Urba WJ, Curti BD (2012) Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches. Clinical Investigation 2: 957-959.

    View at Publisher | View at Google Scholar
  • Urba WJ, Curti BD (2012) advances in immunotherapy and targeted approaches. Clin Invest 2: 957–959.

    View at Publisher | View at Google Scholar
  • 王小彦, 王玉丽, 陈娇, 赵桂龙, 徐为人, 汤立达. 新型糖苷类衍生物降糖作用筛选和研究. 中草药. 2013 Feb;4:454458.

    View at Publisher | View at Google Scholar
  • 王玉丽, 王小彦, 赵桂龙, 邵华, 徐为人, 汤立达. 钠-葡萄糖协同转运蛋白 2 抑制剂类抗糖尿病新药的研发概况. 现代药物与临床. 2012;2:015.

    View at Publisher | View at Google Scholar
  • 任安. 新型抗糖尿病药物研究进展. 安徽医学. 2014(10):1341-3.

    View at Publisher | View at Google Scholar
  • Li S, Qi X, Huang Y, Liu D, Zhou F, Zhou C (2015) Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non–Small-Cell Lung Cancer. Clinical lung cancer 16: 86-91.

    View at Publisher | View at Google Scholar
  • Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, et al. (2015) ( The MET inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient–derived xenograft models. Clinical Cancer Research 21: 2811-2819.

    View at Publisher | View at Google Scholar
  • Wang ZX, Sun J, Howell CE, Zhou QY, He ZX, et al. (2014) Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundamental & clinical pharmacology 28: 551-582.

    View at Publisher | View at Google Scholar
  • Hamilton G, Rath B, Burghuber O (2015)Pharmacokinetics of crizotinib in NSCLC patients. Expert opinion on drug metabolism & toxicology 11: 835-842.

    View at Publisher | View at Google Scholar
  • 吕昕泽, 孙波, 杨微, 于飞, 傅晟. 治疗 2 型糖尿病新药 ipragliflozin. 中国新药杂志. 2015;24(3):241-4.

    View at Publisher | View at Google Scholar
  • Schrödl K, Von Schilling C, Tufman A, Huber RM, Gamarra F (2014) Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance. Respiration 88: 262-264.

    View at Publisher | View at Google Scholar
  • Zhang Y, Jain RK, Zhu M (2015) Recent progress and advances in HGF/MET-targeted therapeutic agents for cancer treatment. Biomedicines 3: 149-181.

    View at Publisher | View at Google Scholar
  • Vrhovac I, Breljak D, Karaica D, Radović N, Jadrijević S et al. HOĆE LI INHIBITORI PRIJENOSA GLUKOZE U TERAPIJI DIJABETESA DJELOVATI SPECIFIČNO U BUBREZIMA?.

    View at Publisher | View at Google Scholar
  • Kurata Y, Miyauchi N, Suno M, Ito T, Sendo T, et al. (2015) Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer. Journal of pharmaceutical health care and sciences 1: 8.

    View at Publisher | View at Google Scholar
  • 曾要富, 姚亮元, 钟爱军, 朱颖熹, 袁秀菊. SGLT2 抑制剂 Canagliflozin——Ⅱ 型糖尿病治疗的新药. 中国现代应用药学. 2014;31(9):1154-60.

    View at Publisher | View at Google Scholar
  • Riessk J (2013) Shifting paradigms in non-small cell lung cancer: an evolving therapeutic landscape. The American journal of managed care 19: s390-s397.

    View at Publisher | View at Google Scholar
  • 徐红燕, 杜有功, 陈赛贞. 钠-葡萄糖协同转运体 2 抑制剂的研究进展. 中国医院用药评价与分析. 2014(6):489-92.

    View at Publisher | View at Google Scholar
  • Pinho JR, Sitnik R, Mangueira CL (2014) Personalized medicine and the clinical laboratory. Einstein (São Paulo) 12: 366-373.

    View at Publisher | View at Google Scholar
  • Geeleher P, Gamazon ER, Seoighe C, Cox NJ, Huang RS (2016) Consistency in large pharmacogenomic studies. Nature Dec 540: E1-E2.

    View at Publisher | View at Google Scholar
  • 黎克江. 治疗糖尿病的热点靶点的研究近况. 中国卫生产业. 2013;10(33):19-20.

    View at Publisher | View at Google Scholar
  • 田培超, 刘玉峰, 王怀立, 罗强, 陈铮, 王越 (2014) 间变性淋巴瘤激酶抑制剂对人神经母细胞瘤细胞凋亡的影响. 中华实验外科杂志. 31: 2006-2008.

    View at Publisher | View at Google Scholar
  • Schwaederle M, Zhao M, Lee JJ (2016) Supplementary Online Content.

    View at Publisher | View at Google Scholar
  • Cass Y, Connor TH, Tabachnik A (2016) Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting. Journal of Oncology Pharmacy Practice. 2016 Mar 22:1078155216637217.

    View at Publisher | View at Google Scholar
  • Piccolo KM, Boullata JI (2015) The Influence of Polypharmacy on Nutrition. InPreventive Nutrition 83-113.

    View at Publisher | View at Google Scholar
  • Nehoff H (2016) The use of combination tyrosine kinase inhibitors for the treatment of glioblastoma multiforme (Doctoral dissertation, University of Otago).

    View at Publisher | View at Google Scholar
  • 劉岡易 (2016) 臺灣晚期 ALK 基因變異陽性非小細胞肺癌患者使用 Crizotinib 作為第一線藥物之成本效用分析. 臺灣大學健康政策與管理研究所學位論文 1: 1-20.

    View at Publisher | View at Google Scholar
  • Rebello Pinho JR, Sitnik R, Pitangueira Mangueira CL (2014) Medicina personalizada e o laboratório clínico. Einstein (16794508) 12.

    View at Publisher | View at Google Scholar
  • Reitamo S, Remitz A. Topical agents for atopic dermatitis.

    View at Publisher | View at Google Scholar
  • Pinho JR, Sitnik R, Mangueira CL (2014) Medicina personalizada e o laboratorio clinico. Medicine Mates 12.

    View at Publisher | View at Google Scholar
  • 张妍, 石远凯, 韩晓红 (2014) 肿瘤药物基因组学研究进展. 中国新药杂志 23: 1999-2003.

    View at Publisher | View at Google Scholar
  • Zhou H, Ji X, Wu Y, Xuan J, Qi Z, et al. (2014) A dual-role of Gu-4 in suppressing HMGB1 secretion and blocking HMGB1 pro-inflammatory activity during inflammation. PLoS one. 9(3):e89634.

    View at Publisher | View at Google Scholar
  • Wu QY, Sun MR, Wu CL, Li Y, Du JJ, et al. Activation of calcium-sensing receptor increases TRPC3/6 expression in T lymphocyte in sepsis. Molecular immunology 64(1):18-25.

    View at Publisher | View at Google Scholar
  • 李志军, 任新生, 李银平. " 三证三法" 及" 菌毒炎并治" 治疗脓毒症的研究进展 [J]. 中国中西医结合外科杂志. 2012 Jul 6;18(6):553-.

    View at Publisher | View at Google Scholar
  • 彭志允, 彭环庆, 林辉文, 唐钟祥, 李烽辉, 王颖菁. 补气养阴活血法治疗脓毒症患者急性肾损伤的临床观察. 辽宁中医杂志. 2015;42(2):326-8.

    View at Publisher | View at Google Scholar
  • Coleman K (2011) Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Current opinion in microbiology 14(5):550-5.

    View at Publisher | View at Google Scholar
  • Maraki S, Samonis G, Karageorgopoulos DE, Mavros MN, Kofteridis D, et al. ( 2012) In vitro antimicrobial susceptibility to isepamicin of 6296 Enterobacteriaceae clinical isolates collected at a tertiary-care University Hospital in Greece. Antimicrobial agents and chemotherapy Mar 5:AAC-06358.

    View at Publisher | View at Google Scholar
  • Hanberger H, Giske CG, Giamarellou H (2011) When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock. Current infectious disease reports 13(5):416.

    View at Publisher | View at Google Scholar
  • Melchers MJ, van Mil AC, Mouton JW (2015) In vitro activity of ceftolozane alone and in combination with tazobactam against extended-spectrum-β-lactamase-harboring Enterobacteriaceae. Antimicrobial agents and chemotherapy 59(8):4521-5.

    View at Publisher | View at Google Scholar
  • Stockfleth E, Sibbring GC, Alarcon I (2016) New topical treatment options for actinic keratosis: a systematic review. Acta dermato-venereologica 96: 17-23.

    View at Publisher | View at Google Scholar
  • Del Rosso JQ, Kircik L, Goldenberg G, Brian B (2014) Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach. The Journal of clinical and aesthetic dermatology (9 Suppl S2-S12): S2.

    View at Publisher | View at Google Scholar
  • Rosso JQ (2016) Ingenol Mebutate Topical Gel. Journal of Clinical & Aesthetic Dermatology 9.

    View at Publisher | View at Google Scholar
  • Wadi J, Haloub N, Al Ahmad M, Samara A, Romman A (2011) Prevalence of meropenem susceptibility among Gram-negative pathogens isolated from intensive care units in Jordan. The International Arabic Journal of Antimicrobial Agents 1(1).

    View at Publisher | View at Google Scholar
  • Mottaghi K. Structure-based Development of Vitamin B5 Analogs and Evaluation of Their Antimicrobial Efficiency against S. aureus and E. coli (Doctoral dissertation, University of Toronto).

    View at Publisher | View at Google Scholar
  • Chávez-Tapia NC, Ridruejo E, Alves de Mattos A, Bessone F, Daruich J, et al. An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Ann Hepatol 12: S3-S5.

    View at Publisher | View at Google Scholar
  • Ridruejo E (2014) Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Expert opinion on drug safety 13: 307-319.

    View at Publisher | View at Google Scholar
  • ADISON WC. Programming microbes to treat superbug infection (Doctoral dissertation, Nanyang Technological University).

    View at Publisher | View at Google Scholar
  • Liapikou A, Cilloniz C, Mensa J, Torres A (2015) New antimicrobial approaches to gram positive respiratory infections. Pulmonary pharmacology & therapeutics 32: 137-143.

    View at Publisher | View at Google Scholar
  • 高会洲, 杨科武. 超级细菌耐药靶酶金属 β-内酰胺酶的研究进展. 中国药学杂志. 2012;47(5):325-30.

    View at Publisher | View at Google Scholar
  • Liapikou A, Torres A (2013) Emerging drugs on methicillin-resistant Staphylococcus aureus. Expert opinion on emerging drugs 18: 291-305.

    View at Publisher | View at Google Scholar
  • Liapikou A, Rosales-Mayor E, Torres A (2014) Pharmacotherapy for hospital-acquired pneumonia. Expert opinion on pharmacotherapy 15: 775-786.

    View at Publisher | View at Google Scholar
  • Liapikou A, Dimakou K, Toumbis M (2016) Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience. Therapeutic Advances in Respiratory Disease 10: 368-378.

    View at Publisher | View at Google Scholar
  • Kim C, Yang H, Fukushima Y, Saw PE, Lee J, et al. (2014) Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. Cancer cell 25: 102-117.

    View at Publisher | View at Google Scholar
  • Stephen S, Baranova A, Younossi ZM (2012) Nonalcoholic fatty liver disease and bariatric surgery. Expert review of gastroenterology & hepatology 6(2):163-71.

    View at Publisher | View at Google Scholar
  • Sanghai N, Jain V, Preet R, Kandekar S, Das S, et al. ( 2014) Combretastatin A-4 inspired novel 2-aryl-3-arylamino-imidazo-pyridines/pyrazines as tubulin polymerization inhibitors, antimitotic and anticancer agents. MedChemComm 5: 766-782.

    View at Publisher | View at Google Scholar
  • Devkota L, Lin CM, Strecker TE, Wang Y, Tidmore JK, et al. (2016) Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents. Bioorganic & medicinal chemistry 24: 938-956.

    View at Publisher | View at Google Scholar
  • Rezazadeh A, Yazdanparast R, Molaei M (2012) Amelioration of diet-induced nonalcoholic steatohepatitis in rats by Mn-salen complexes via reduction of oxidative stress. Journal of biomedical science 19(1):26.

    View at Publisher | View at Google Scholar
  • Stocker V, Ghinet A, Leman M, Rigo B, Millet R, et al. (2013) On the synthesis and biological properties of isocombretastatins: a case of ketone homologation during Wittig reaction attempts. RSC Advances 3: 3683-3696.

    View at Publisher | View at Google Scholar
  • Yan GH, Li XF, Ge BC, Shi XD, Chen YF, et al. (2015) Synthesis and anticancer activities of 3-arylflavone-8-acetic acid derivatives. European journal of medicinal chemistry 90: 251-257.

    View at Publisher | View at Google Scholar
  • Xin HG, Zhang BB, Wu ZQ, Hang XF, Xu WS et al. (2014) Treatment with baicalein attenuates methionine− choline deficient diet-induced non-alcoholic steatohepatitis in rats. European journal of pharmacology 738:310-8.

    View at Publisher | View at Google Scholar
  • Herdman CA, Devkota L, Lin CM, Niu H, Strecker TE, et al. (2015) Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization. Bioorganic & medicinal chemistry 23: 7497-520.

    View at Publisher | View at Google Scholar
  • Драпкина ОМ, Смирин ВИ, Ивашкин ВТ. Патогенез, лечение и эпидемиология НАЖБП–что нового? Эпидемиология НАЖБП в России. Русский медицинский журнал. 2011;19(28).

    View at Publisher | View at Google Scholar
  • Shi TT, Li G, Xiao HT (2016) The Role of RhoJ in Endothelial Cell Biology and Tumor Pathology. BioMed Research International 2016.

    View at Publisher | View at Google Scholar
  • Baguley BC, McKeage MJ (2014) Therapeutic targeting of tumor angiogenesis: how far have we come?. Clinical Investigation 4: 1113-1122.

    View at Publisher | View at Google Scholar
  • Wang W, Zhou W, Wang B, Zhu H, Ye L et al. (2012) Antioxidant effect of apolipoprotein AI on high-fat diet-induced non-alcoholic fatty liver disease in rabbits. Acta biochimica et biophysica Sinica Nov 21:gms100

    View at Publisher | View at Google Scholar
  • Herdman CA, Strecker TE, Tanpure RP, Chen Z, Winters A, et al. (2016) Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization. MedChemComm 7: 2418-2427.

    View at Publisher | View at Google Scholar
  • Koh GY, Kim C, Yang H, Do Heo W, Kim I, et al. (2014) inventors; Korea Advanced Institute Of Science, Technology (Kaist), assignee. Method for targeting vascular rhoj for inhibiting tumor angiogenesis. United States patent application US 14/271,117.

    View at Publisher | View at Google Scholar
  • Зайченко ОЕ. Терапевтические мишени при неалкогольной жировой болезни печени. Сучасна гастроентерологія. 2014(1):130-8.

    View at Publisher | View at Google Scholar
  • Степанов ЮМ. Стеатоз печени и стеатогепатит—неизбежность смешанного генеза. Гастроентерологiя. 2014;54(4).

    View at Publisher | View at Google Scholar
  • Lim E, Ni M, Cao S, Hazra A, Tamimi RM, et al. (2014) Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy. Current breast cancer reports. 6: 71-78.

    View at Publisher | View at Google Scholar
  • Звягинцева ТД, Глущенко СВ. Неалкогольный стеатогепатит и методы патогенетический коррекции. Международный медицинский журнал. 2014(2):29-32.

    View at Publisher | View at Google Scholar
  • LEGHI GE, DOMENICI FA, VANNUCCHI H (2015) Influence of oxidative stress and obesity in patients with nonalcoholic steatohepatitis. Arquivos de gastroenterologia 52(3):228-33.

    View at Publisher | View at Google Scholar
  • Авалуева ЕБ, Ткаченко ЕИ, Сказываева ЕВ, Иванов СВ, Оришак ЕА, Лапинский ИВ. Эффективность урсодеоксихолевой кислоты в терапии неалкогольной жировой болезни печени, ассоциированной с метаболическим синдромом. Экспериментальная и клиническая гастроэнтерология. 2013(11).

    View at Publisher | View at Google Scholar
  • Stepanov YM (2014) Hepatic Steatosis and Steatohepatitis Is the Inevitability of Mixed Genesis. GASTROENTEROLOGY (4.54):136-42.

    View at Publisher | View at Google Scholar
  • Скибчик ВА, Башта ГВ, Булак ОВ. СТАТИНЫ В ТЕРАпИИ НЕАЛКОГОЛьНОЙ ЖИРОВОЙ БОЛЕЗНИ пЕчЕНИ: ВЫСОКАЯ ЭФФЕКТИВНОСТь И БЕЗОпАСНОСТь. НАУКОВО-ПРАКТИЧНИЙ МЕДИЧНИЙ.:68.

    View at Publisher | View at Google Scholar
  • Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW et al. (2012) Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. European journal of endocrinology 167(5):643-50

    View at Publisher | View at Google Scholar
  • Hoftijzer HC (2011) Differentiated thyroid carcinoma: treatment and clinical consequences of therapy. Department of Endocrinology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University May 12.

    View at Publisher | View at Google Scholar
  • Hareedy A, Mostafa R. Clinical and molecular studies on differentiated thyroid carcinoma management (Doctoral dissertation, Thyroid Research Group, Department of Endocrinology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University).

    View at Publisher | View at Google Scholar
  • Todenhöfer T, Hennenlotter J, Schmiedel BJ, Hohneder A, Grimm S, et al. (2013) Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases. The Prostate 73(2):162-8.

    View at Publisher | View at Google Scholar
  • Todenhöfer T, Schwentner C, Schilling D, Gakis G, Stenzl A (2011) Behandlung von ossären Metastasen und therapieinduzierter Osteoporose beim Prostatakarzinom. Der Urologe 50(9):1055.

    View at Publisher | View at Google Scholar
  • Grabowski GA, Golembo M, Shaaltiel Y. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. Molecular genetics and metabolism. 2014 May 31;112(1):1-8.

    View at Publisher | View at Google Scholar
  • Castilho A, Steinkellner H (2012) Glyco‐engineering in plants to produce human‐like N‐glycan structures. Biotechnology journal 7(9):1088-98.

    View at Publisher | View at Google Scholar
  • Elstein D, Hughes D, Goker‐Alpan O, Stivel M, Baris HN, et al. (2014) Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease. Journal of Obstetrics and Gynaecology Research 40(4):968-75.

    View at Publisher | View at Google Scholar
  • Barth BM, Shanmugavelandy SS, Tacelosky DM, Kester M, Morad SA, et al. (2013) Gaucher's disease and cancer: a sphingolipid perspective. Critical Reviews™ in Oncogenesis 18(3).

    View at Publisher | View at Google Scholar
  • Rosales-Mendoza S, Tello-Olea MA (2015) Carrot cells: a pioneering platform for biopharmaceuticals production. Molecular biotechnology 57(3):219-32.

    View at Publisher | View at Google Scholar
malatya escort ankara escort ankara escort antalya escort ankara escort istanbul escort porno izle
mobile bitcoin casino